TScan Therapeutics, Inc. financial data

Symbol
TCRX on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
880 Winter Street, Waltham, MA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 12, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 726 % +5.55%
Debt-to-equity 63 % -23.8%
Return On Equity -58.7 % +10.7%
Return On Assets -36 % -0.03%
Operating Margin -1.28K % -138%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 24M shares
Entity Public Float 74.5M USD -99.8%
Weighted Average Number of Shares Outstanding, Basic 119M shares +25.2%
Weighted Average Number of Shares Outstanding, Diluted 119M shares +25.2%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 9.36M USD -44.7%
Research and Development Expense 100M USD +23.4%
General and Administrative Expense 28.4M USD +7.95%
Operating Income (Loss) -119M USD -31.6%
Net Income (Loss) Attributable to Parent -111M USD -26%
Earnings Per Share, Basic -0.53 USD/shares +78.5%
Earnings Per Share, Diluted -0.53 USD/shares +78.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 133M USD -14.2%
Marketable Securities, Current 138M USD +129%
Accounts Receivable, after Allowance for Credit Loss, Current 31.9M USD
Assets, Current 274M USD +26%
Property, Plant and Equipment, Net 7.46M USD -13.2%
Operating Lease, Right-of-Use Asset 59.6M USD +1.89%
Assets 348M USD +19.4%
Accounts Payable, Current 3.65M USD +14.1%
Employee-related Liabilities, Current 4.8M USD +19.9%
Liabilities, Current 28.7M USD -13.5%
Operating Lease, Liability, Noncurrent 55.8M USD +5.98%
Other Liabilities, Noncurrent 146K USD +1117%
Liabilities 119M USD -2.84%
Retained Earnings (Accumulated Deficit) -339M USD -48.8%
Stockholders' Equity Attributable to Parent 229M USD +35.6%
Liabilities and Equity 348M USD +19.4%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -29.3M USD -24.1%
Net Cash Provided by (Used in) Financing Activities 258K USD
Net Cash Provided by (Used in) Investing Activities 36.2M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 7.15M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 138M USD -13.8%
Interest Paid, Excluding Capitalized Interest, Operating Activities 758K USD +2.02%
Deferred Tax Assets, Valuation Allowance 82.2M USD +58.6%
Operating Lease, Liability 62.4M USD +10%
Depreciation 1.25M USD -16.3%
Payments to Acquire Property, Plant, and Equipment 705K USD -15.9%
Lessee, Operating Lease, Liability, to be Paid 95.9M USD +6.92%
Property, Plant and Equipment, Gross 22.3M USD +9.94%
Operating Lease, Liability, Current 3.9M USD -10.9%
Lessee, Operating Lease, Liability, to be Paid, Year Two 10.5M USD +17.2%
Lessee, Operating Lease, Liability, to be Paid, Year One 9.51M USD +5.24%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 33.5M USD +1.57%
Lessee, Operating Lease, Liability, to be Paid, Year Three 10.9M USD +35.7%
Deferred Tax Assets, Operating Loss Carryforwards 23.2M USD -0.81%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 11.3M USD +35.5%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 99.6M USD +45.9%
Interest Expense 3.72M USD -2.44%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares